Telomere length and DNA methylation epitype both provide independent prognostic information in CLL patients; data from the UK CLL4, ARCTIC and ADMIRE clinical trials.

The article from the British Journal of Haematology discusses the validation of two biomarkers, methylation-based epitype (DME) and telomere length (TL), in chronic lymphocytic leukaemia (CLL) patients using data from UK clinical trials. The study found that both DME and TL provide independent prognostic information, with TL-S predicting poorer progression-free and overall survival. The research highlights the potential of these biomarkers in enhancing risk-adapted stratification of CLL patients and suggests the need for further studies with larger cohorts to identify patients who may benefit from targeted agents. [Extracted from the article]